Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

173.95 -4.99 (-2.79%)
Delayed Quote Updated: 3:59 PM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Repligen: 3 Key Takeaways for Long-Term Investors ↗
Services revenue is building a recurring base while capital orders suggest stronger sales ahead. 
Via The Motley Fool
Topics Earnings
News headline image
1 mid-cap stock with exciting potential and 2 facing headwinds
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
News headline image
5 must-read analyst questions from Repligen’s Q3 earnings call
Repligen’s third quarter was marked by revenue and non-GAAP profit that exceeded Wall Street expectations, driving a positive market reaction. Management att... 
Via StockStory
Topics Earnings
News headline image
RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 10.9% year ... 
Via StockStory
Topics Artificial Intelligence
Repligen Corp (NASDAQ:RGEN) Combines Strong Growth with a Constructive Technical Setup ↗
Via Chartmill
Repligen (NASDAQ:RGEN) Combines Strong Growth with a Promising Technical Breakout Setup ↗
Via Chartmill
News headline image
Repligen (RGEN) Q3 2026 Earnings Call Transcript ↗
BioLife acquisition bolsters cell therapy as chromatography and proteins surge. 
Via The Motley Fool
Topics Earnings
News headline image
What Repligen (RGEN) Said on Its Q3 Earnings Call ↗
Repligen (NASDAQ:RGEN) reported record third-quarter 2026 revenue of $209 million, surpassing its prior quarterly peak set in the second quarter of 2022, as growth in its Proteins, Chromatography and... 
Via MarketBeat
Topics Earnings
News headline image
Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 10.9% yea... 
Via StockStory
Repligen (NASDAQ:RGEN) Rallies as Quality Stock Delivers Earnings Beat ↗
Via Chartmill
News headline image
Repligen (RGEN) Q3 earnings report preview: what to look for
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting earnings this Tuesday before market hours. Here’s what to expect. Replig... 
Via StockStory
Topics Artificial Intelligence
News headline image
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields r... 
Via StockStory
Topics Bonds Economy
News headline image
Why Freshworks Stock Bumped Higher Today ↗
It's about to join a famous small-cap stock index. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
News headline image
3 Healthcare Stocks That Concern Us
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be... 
Via StockStory
News headline image
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead
Over the past six months, Repligen has been a great trade, beating the S&P 500 by 18.1%. Its stock price has climbed to $168.43, representing a healthy 31.7%... 
Via StockStory
Topics Stocks
News headline image
1 Profitable Stock on Our Buy List and 2 We Brush Off
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
3 High-Flying Stocks with Warning Signs
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
Topics Supply Chain
News headline image
3 Hyped Up Stocks We Keep Off Our Radar
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos... 
Via StockStory
News headline image
Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
News headline image
2 Growth Stocks to Add to Your Roster and 1 We Avoid
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
Topics Credit Cards
News headline image
Why Repligen (RGEN) Stock Is Up Today
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 14.6% in the afternoon session after the company reported ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Repligen Q2 Earnings Call Highlights ↗
Repligen (NASDAQ:RGEN) reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring... 
Via MarketBeat
Topics Earnings
Which stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.9% ... 
Via StockStory
News headline image
Repligen (RGEN) Q2 Earnings: What To Expect
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday morning. Here’s what you need to know. Repligen bea... 
Via StockStory
News headline image
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC... 
Via StockStory
News headline image
3 Cash-Producing Stocks That Concern Us
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
News headline image
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach ↗
Repligen (NASDAQ:RGEN) said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that... 
Via MarketBeat
News headline image
Why Repligen (RGEN) Stock Is Trading Lower Today
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 7% in the morning session after investors reacted to the com... 
Via StockStory
News headline image
3 Reasons RGEN is Risky and 1 Stock to Buy Instead
Over the last six months, Repligen’s shares have sunk to $139.83, producing a disappointing 16% loss - a stark contrast to the S&P 500’s 9% gain. This might ... 
Via StockStory
Topics Stocks Supply Chain
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.